Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06454188 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
A Phase 4 study of Psoriatic Arthritis and Spondyloarthritis, Axial, sponsored by Care Arthritis.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT06454188: Recruiting Phase 4 study of Psoriatic Arthritis and Spondyloarthritis, Axial, sponsored by Care Arthritis.
NCT06454188 is a Phase 4 study of Psoriatic Arthritis and Spondyloarthritis, Axial that is actively recruiting participants, run by Care Arthritis. The registered enrollment target is 100 participants, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06454188, a Phase 4 study of Psoriatic Arthritis and Spondyloarthritis, Axial, is actively recruiting participants, sponsored by Care Arthritis.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Upadacitinib 15 MG [Rinvoq]
Study Locations (4)
Oregon
- Oregon Health and Science University - Portland
Texas
- DM Clinical Research - Tomball
Ontario
- The Ottawa Hospital Research Institute - Ottawa
Quebec
- Groupe de Recherche en Maladies Osseuses (G.R.M.O.) Inc. - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-11-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What NCT06454188 shows while recruiting
NCT06454188 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06454188 reports a single indexed study location in Oregon, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT06454188 about?
NCT06454188 is a clinical study titled "A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis". A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
What is the current status of trial NCT06454188?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-11-06. Estimated completion is 2026-12.
What conditions does trial NCT06454188 study?
This clinical trial studies the following conditions: Psoriatic Arthritis, Spondyloarthritis, Axial.
What interventions are being tested in trial NCT06454188?
The interventions under investigation include: Placebo (DRUG), Upadacitinib 15 MG [Rinvoq] (DRUG).
Who is sponsoring clinical trial NCT06454188?
This trial is sponsored by Care Arthritis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06454188 being conducted?
This trial has 4 study locations across Oregon, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06454188's enrollment target sits among peer trials
100 37th of 48 higher than 11 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
RECRUITING · Phase 4
-
Centocor Microarray Study of Patients
COMPLETED · Phase 4
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Stronger Together Psoriatic Arthritis Wellness Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI